OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lee on Second-Line Treatment Options in RCC

May 12th 2020

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Dr. Smaglo on Novel Therapies in Advanced Gastric Cancer

May 12th 2020

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Dr. Goy on Research Efforts With BTK Inhibitors in MCL

May 11th 2020

Andre Goy, MD, MS, discusses research efforts with BTK inhibitors in mantle cell lymphoma.

Dr. Smith on Safety Profiles of BTK Inhibitors in MCL

May 11th 2020

Sonali M. Smith, MD, discusses the different safety profiles of BTK inhibitors in mantle cell lymphoma.

Dr. Wang on the Utility of CAR T-Cell Therapy in Relapsed/Refractory MCL

May 11th 2020

Michael Wang, MD, discusses the utility of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.

Dr. Westin on Novel Targets in Endometrial Cancer

May 11th 2020

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Dr. Freedland on Real-World Utility of Enzalutamide in Prostate Cancer

May 11th 2020

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Dr. Anderson on Recent Advances With Novel Therapies in Multiple Myeloma

May 11th 2020

Larry Anderson, MD, PhD, discusses recent advances made with novel therapies in multiple myeloma.

Dr. Lee on Second-Line Treatment Options in RCC

May 11th 2020

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Dr. Smaglo on Novel Therapies in Advanced Gastric Cancer

May 11th 2020

Brandon G. Smaglo, MD, FACP, discusses novel therapies in advanced gastric cancer.

Dr. Raez on State of Lung Cancer Treatment in Light of COVID-19

May 11th 2020

Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Hughes on Mutational Risk in Oncology

May 9th 2020

Kevin Hughes, MD, discusses mutational risk in oncology.

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

May 9th 2020

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Dr. Burke on Research With Tafasitamab in Lymphoma

May 9th 2020

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Dr. Accordino on Utility of Liquid Biopsies in Breast Cancer

May 9th 2020

Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.

Dr. Braunstein on Quadruplet Therapies in Multiple Myeloma

May 9th 2020

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian Cancer

May 8th 2020

Thomas Herzog, MD, discusses the data that led to the FDA approval of the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiency–positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.

Dr. Hamilton on the Evolution of Treatment in HER2+ Breast Cancer

May 8th 2020

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.